The FDA approved Merus N.V.'s Bizengri for pancreatic adenocarcinoma and NSCLC patients with NRG1 gene fusion. It is the first approved medicine from Merus, based on Biclonics technology.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Merus Scores Its First FDA Approval For Lung Cancer Drug
